ERBB2 and neoplasm: Figure 2 showcases real-world stained images of HER2 IHC and ISH in solid tumors. While the inter-observer agreement is generally better at differentiating IHC 0 and 1+ from 3+ cases, high interobserver variability can occur in discerning 2+ from 3+ scores, which can ultimately influence the eligibility for tumor-agnostic therapy (38, 39).